← Leaderboards
Markus Mãschen
Yale University
$33,184,326
Attributed
$34,409,745
Total exposure
15
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,409,745 · 15
By mechanism
R01$20,794,246 · 9
R35$10,701,847 · 1
P01$2,536,071 · 4
R21$377,581 · 1
Top collaborators
- Eric Meffre4 shared
Most similar at Yale University
Same institution · by research overlap
- Erol Fikrig$57,005,638
- Jordan S Pober$30,894,969
- Nancy Maizels$17,573,272
- Insoo Kang$13,126,166
- William M Philbrick$3,904,515
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsSignal TransductionB-LymphocytesDrug ResistanceOncogenicBaseMediatingMouse ModelGeneticCell DeathMalignant NeoplasmsRelapsePathway InteractionsPre-ClinicalPreventMalignant - DescriptorReceptor SignalingToxic EffectB Lymphoid MalignancyB-Cell LymphomasLeukemiaInhibitor/AntagonistResponseLesion
Grant awards (69)
Lymphoid-specific high-efficiency beta-catenin protein degradation$3,131,408
R01 · FY2025 · AI · contact PI
Metabolic gatekeepers in B-cell malignancies$1,004,945
R35 · FY2025 · CA · contact PI
Targeting GSK3B in refractory B-cell malignancies$612,308
R01 · FY2025 · CA · contact PI
SYK and ZAP70 kinases in lymphocyte selection$598,819
R01 · FY2025 · AI · contact PI
Central tolerance mechanisms in B-cell malignancies$402,275
R01 · FY2025 · CA · contact PI
Metabolic gatekeepers in B-cell malignancies$954,744
R35 · FY2024 · CA · contact PI
SYK and ZAP70 kinases in lymphocyte selection$617,340
R01 · FY2024 · AI · contact PI
Targeting GSK3B in refractory B-cell malignancies$572,454
R01 · FY2024 · CA · contact PI
Central tolerance mechanisms in B-cell malignancies$382,161
R01 · FY2024 · CA · contact PI
Metabolic gatekeepers in B-cell malignancies$984,894
R35 · FY2023 · CA · contact PI
SYK and ZAP70 kinases in lymphocyte selection$617,340
R01 · FY2023 · AI · contact PI
Targeting GSK3B in refractory B-cell malignancies$610,056
R01 · FY2023 · CA · contact PI
Targeting oncogenic TCR signaling in PTCL$476,845
P01 · FY2023 · CA · contact PI
Central tolerance mechanisms in B-cell malignancies$402,275
R01 · FY2023 · CA · contact PI
Administrative Core$94,663
P01 · FY2023 · CA · contact PI
Metabolic gatekeepers in B-cell malignancies$984,900
R35 · FY2022 · CA · contact PI
SYK and ZAP70 kinases in lymphocyte selection$617,340
R01 · FY2022 · AI · contact PI
Targeting oncogenic TCR signaling in PTCL$447,122
P01 · FY2022 · CA · contact PI
Central tolerance mechanisms in B-cell malignancies$419,150
R01 · FY2022 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$166,743
R01 · FY2022 · CA · contact PI
Administrative Core$129,200
P01 · FY2022 · CA · contact PI
Metabolic gatekeepers in B-cell malignancies$1,005,000
R35 · FY2021 · CA · contact PI
Metabolic basis of B cell lineage leukemia relapse$1,002,111
R35 · FY2021 · CA · contact PI
Targeting oncogenic TCR signaling in PTCL$456,247
P01 · FY2021 · CA · contact PI
Targeted activation of autoimmune checkpoints in B cell malignancies$397,813
R01 · FY2021 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$383,156
R01 · FY2021 · CA · contact PI
Metabolic basis of B cell lineage leukemia relapse$1,035,016
R35 · FY2020 · CA · contact PI
Targeting oncogenic TCR signaling in PTCL$456,247
P01 · FY2020 · CA · contact PI
Targeted activation of autoimmune checkpoints in B cell malignancies$410,875
R01 · FY2020 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$169,192
R01 · FY2020 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$50,812
R01 · FY2020 · CA · contact PI
Metabolic basis of B cell lineage leukemia relapse$1,003,965
R35 · FY2019 · CA · contact PI
Targeting oncogenic TCR signaling in PTCL$475,747
P01 · FY2019 · CA · contact PI
Targeted activation of autoimmune checkpoints in B cell malignancies$398,548
R01 · FY2019 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$383,865
R01 · FY2019 · CA · contact PI
Metabolic basis of B cell lineage leukemia relapse$1,035,561
R35 · FY2018 · CA · contact PI
Targeted activation of autoimmune checkpoints in B cell malignancies$410,875
R01 · FY2018 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$395,738
R01 · FY2018 · CA · contact PI
Metabolic basis of B cell lineage leukemia relapse$1,036,898
R35 · FY2017 · CA · contact PI
Targeted activation of autoimmune checkpoints in B cell malignancies$410,875
R01 · FY2017 · CA · contact PI
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics$395,738
R01 · FY2017 · CA · contact PI
Metabolic basis of B cell lineage leukemia relapse$653,813
R35 · FY2016 · CA · contact PI
PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA$356,625
R01 · FY2016 · CA · contact PI
PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA$356,156
R01 · FY2015 · CA · contact PI
Targeting BCL6 in tyrosine kinase-driven leukemia$328,714
R01 · FY2015 · CA · contact PI
Negative feedback signaling in tyrosine kinase-driven leukemia$328,714
R01 · FY2015 · CA · contact PI
Infectious origins of childhood leukemia$328,629
R01 · FY2015 · CA · contact PI
PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA$354,563
R01 · FY2014 · CA · contact PI
Negative feedback signaling in tyrosine kinase-driven leukemia$317,679
R01 · FY2014 · CA · contact PI
Targeting BCL6 in tyrosine kinase-driven leukemia$317,679
R01 · FY2014 · CA · contact PI
Infectious origins of childhood leukemia$317,512
R01 · FY2014 · CA · contact PI
Negative feedback signaling in tyrosine kinase-driven leukemia$325,775
R01 · FY2013 · CA · contact PI
Targeting BCL6 in tyrosine kinase-driven leukemia$325,602
R01 · FY2013 · CA · contact PI
Infectious origins of childhood leukemia$305,984
R01 · FY2013 · CA · contact PI
Pre-B cell receptor signaling in acute lymphoblastic leukemia$296,649
R01 · FY2013 · CA · contact PI
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia$296,649
R01 · FY2013 · CA · contact PI
Infectious origins of childhood leukemia$324,738
R01 · FY2012 · CA · contact PI
Pre-B cell receptor signaling in acute lymphoblastic leukemia$322,040
R01 · FY2012 · CA · contact PI
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia$322,040
R01 · FY2012 · CA · contact PI
Infectious origins of childhood leukemia$7,262
R01 · FY2012 · CA · contact PI
Infectious origins of childhood leukemia$332,000
R01 · FY2011 · CA · contact PI
Pre-B cell receptor signaling in acute lymphoblastic leukemia$322,040
R01 · FY2011 · CA · contact PI
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia$322,040
R01 · FY2011 · CA · contact PI
Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia$168,781
R21 · FY2011 · CA · contact PI
Pre-B cell receptor signaling in acute lymphoblastic leukemia$332,000
R01 · FY2010 · CA · contact PI
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia$332,000
R01 · FY2010 · CA · contact PI
Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia$208,800
R21 · FY2010 · CA · contact PI
Pre-B cell receptor signaling in acute lymphoblastic leukemia$332,000
R01 · FY2009 · CA · contact PI
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia$332,000
R01 · FY2009 · CA · contact PI